Latest Insider Transactions at Cyclacel Pharmaceuticals, Inc. (CYCC)
This section provides a real-time view of insider transactions for Cyclacel Pharmaceuticals, Inc. (CYCC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Cyclacel Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Cyclacel Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 12
2025
|
Wong Sing Ee Doris Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
300,178
+21.27%
|
$300,178
$1.4 P/Share
|
|
Nov 12
2025
|
Cu Seng Kiu Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+50.0%
|
$200,000
$1.4 P/Share
|
|
Nov 05
2025
|
Yee Lung Ong > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
467,535
+50.0%
|
-
|
|
Nov 05
2025
|
Khai Loon Kua > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
467,535
+50.0%
|
-
|
|
Nov 05
2025
|
Kim Choy Yap > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
467,535
+50.0%
|
-
|
|
Nov 05
2025
|
Kim Choy Yap > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
28,540
-100.0%
|
$28,540
$1.7 P/Share
|
|
Oct 30
2025
|
Yee Lung Ong > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
248,814
-100.0%
|
$248,814
$1.8 P/Share
|
|
Oct 30
2025
|
Khai Loon Kua > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
242,477
-100.0%
|
$242,477
$1.8 P/Share
|
|
Oct 30
2025
|
Kim Choy Yap > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
112,260
-79.75%
|
$112,260
$1.81 P/Share
|
|
Oct 29
2025
|
Kim Choy Yap > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
110,749
-44.03%
|
$110,749
$1.83 P/Share
|
|
Oct 28
2025
|
Kim Choy Yap > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
13,111
-4.95%
|
$13,111
$1.83 P/Share
|
|
Oct 27
2025
|
Kim Choy Yap > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
120,250
-31.24%
|
$240,500
$2.12 P/Share
|
|
Oct 24
2025
|
Kim Choy Yap > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
19,595
-4.84%
|
$19,595
$1.9 P/Share
|
|
Oct 24
2025
|
Yee Lung Ong > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
19,858
-7.39%
|
$19,858
$1.99 P/Share
|
|
Oct 21
2025
|
Diversified Berhad Fitters > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
92,352
-24.85%
|
$277,056
$3.0 P/Share
|
|
Oct 20
2025
|
Diversified Berhad Fitters > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
108,107
-22.54%
|
$324,321
$3.09 P/Share
|
|
Oct 16
2025
|
Diversified Berhad Fitters > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
26,051
-5.15%
|
$130,255
$5.5 P/Share
|
|
Oct 16
2025
|
Khai Loon Kua > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
88,204
-26.67%
|
$352,816
$4.22 P/Share
|
|
Oct 15
2025
|
Khai Loon Kua > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
7,479
-2.21%
|
$37,395
$5.66 P/Share
|
|
Oct 14
2025
|
Yee Lung Ong > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
135,793
-33.57%
|
$814,758
$6.0 P/Share
|
|
Oct 10
2025
|
Diversified Berhad Fitters > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
51,400
-9.23%
|
$257,000
$5.26 P/Share
|
|
Oct 08
2025
|
Diversified Berhad Fitters > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
142,000
-20.31%
|
$710,000
$5.29 P/Share
|
|
Sep 16
2025
|
Khai Loon Kua > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
25,000
-6.88%
|
$125,000
$5.13 P/Share
|
|
Sep 12
2025
|
Khai Loon Kua > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
22,251
-5.77%
|
$133,506
$6.22 P/Share
|
|
Sep 05
2025
|
Khai Loon Kua > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
19,054
-4.71%
|
$133,378
$7.01 P/Share
|
|
Sep 04
2025
|
Yee Lung Ong > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
186,465
+31.55%
|
-
|
|
Sep 04
2025
|
Khai Loon Kua > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
186,465
+31.55%
|
-
|
|
Sep 04
2025
|
Kim Choy Yap > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
186,465
+31.55%
|
-
|
|
Jul 30
2025
|
David E. Lazar > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
6,750
-4.15%
|
$81,000
$12.36 P/Share
|
|
Feb 26
2025
|
David E. Lazar > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
194,628,820
-100.0%
|
$0
$0.03 P/Share
|
|
Feb 26
2025
|
David E. Lazar > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Direct |
194,628,820
+49.83%
|
-
|
|
Jan 02
2025
|
David Natan Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
Jan 29
2024
|
Brian Schwartz Interim Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+45.12%
|
-
|
|
Dec 21
2023
|
Spiro George Rombotis President and CEO |
BUY
Open market or private purchase
|
Direct |
6,070
+8.12%
|
$18,210
$3.31 P/Share
|
|
Dec 21
2023
|
Paul Mc Barron Director |
BUY
Open market or private purchase
|
Direct |
1,886
+5.35%
|
$5,658
$3.31 P/Share
|
|
Jun 30
2023
|
Brian Schwartz Interim Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,219
+34.32%
|
-
|
|
Jun 30
2023
|
Christopher S Henney Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,219
+35.0%
|
-
|
|
Jun 30
2023
|
Kenneth M. Ferguson Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,219
+32.07%
|
-
|
|
Jun 30
2023
|
Karin L Walker Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,219
+34.32%
|
-
|
|
Jun 30
2023
|
Robert J. Spiegel Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,219
+35.0%
|
-
|
|
Jun 30
2023
|
Sam L Barker Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,219
+34.43%
|
-
|
|
Jan 31
2023
|
Paul Mc Barron Director |
BUY
Grant, award, or other acquisition
|
Direct |
31,200
+49.77%
|
-
|
|
Jan 31
2023
|
Mark Kirschbaum Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,200
+50.0%
|
-
|
|
Jan 31
2023
|
Spiro George Rombotis President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
57,600
+47.92%
|
-
|
|
Jun 14
2022
|
Sam L Barker Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,822
+45.18%
|
-
|
|
Jun 14
2022
|
Christopher S Henney Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,822
+46.51%
|
-
|
|
Jun 14
2022
|
Brian Schwartz Interim Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,822
+44.94%
|
-
|
|
Jun 14
2022
|
Lloyd Sems Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,822
+46.51%
|
-
|
|
Jun 14
2022
|
Robert J. Spiegel Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,822
+46.51%
|
-
|
|
Jun 14
2022
|
Karin L Walker Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,822
+44.94%
|
-
|